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cDNAs coding for the full-length human 65 and 67 kDa glutamic acid decarboxylases
(GADUB and GAD67) were amplified from pancreas and hippocampus cDNA libraries by
polymerase chain reaction, respectively. Both cDNAs were inserted into a baculovirus
vector which mediated highly efficient expression of the human GAD95 and GAD67 with
histidine-hexapeptides as affinity ligands at their C-termini in Spodoptera frugiperda
(Sf9) cells. The recombinant GAD proteins were purified to homogeneity by affinity
chromatography using a metal-chelating matrix. The infected Sf9 insect cells expressed the
recombinant human GAD65 and GAD67 with natural-like conformations, as confirmed by
measurement of their enzyme activities as well as their fully restored autoantigenicities.
Immunoprecipitation of metabolically labeled infected Sf9 cells demonstrated the autoanti-
genic potential of the recombinant GAD proteins. The practicability of using recombinant
GAD65 and GAD67 derived from the baculovirus expression system for the development of
an immunoassay for the diagnosis of insulin-dependent diabetes mellitus is discussed.
Type 1 (insulin-dependent) diabetes mellitus (EDDM)
results from selective destruction of the insulin-producing
y9-cells of the pancreas mediated by a chronic, clinically
silent, autoimmune process (1, 2). The detection of circu-
lating islet cell specific autoantibodies in non-diabetic
individuals indicates a risk for IDDM and has lead to a
search for the /?-cell specific components that may be the
targets of this autoimmune response (3, 4). Autoantibodies
directed to a 64 kDa protein seem to be the earliest
detectable /?-cell antibodies, being found up to 8 years
before the clinical onset of IDDM in 80-90% of patients (5-
12). The 64 kDa islet antigen representing one of the major
target antigens in IDDM has been identified as glutamic
acid decarboxylase (GAD). GAD is also expressed in brain
tissue (13). Recent studies of GAD expression and puri-
fication have demonstrated at least two isoforms of GAD,
with apparent molecular masses of 65 kDa (GAD66) and 67
kDa (GAD67), which are encoded by two genes located on
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two different chromosomes (14, 15). Both GAD65 and
GAD67 are expressed in islet cells, and both forms are
recognized by sera from patients with IDDM (16-21).
Reliable measurement of these anti-GAD autoantibodies is
considered to be highly predictive of the development of
IDDM and coincides with the gradual loss of /9-cells. Early
diagnosis will provide an opportunity for treatments that
may forestall or prevent serious health problems usually
associated with the clinical stage of IDDM.
If GAD proves to be one of the primary antigen(s) in the
pathogenesis of IDDM, the corresponding autoantibodies in
the sera of patients with IDDM should be an important
diagnostic marker for the clinical manifestation of IDDM or
prediabetic insulitis. In order to obtain large amounts of
natural and autoantigenic human GAD66 and GAD97 it was
necessary to take advantage of recombinant DNA tech-
niques combined with a suitable eukaryotic expression
system. In this report we describe the isolation of cDNA
clones coding for the full-length human GAD65 and GAD<,7,
and their high level expression as fusion proteins with
histidine-hexapeptides at their C-termini in Spodoptera
frugiperda (Sf9) cells mediated by a recombinant bacu-
lovirus. The histidine-hexapeptide fusion moiety allowed
the specific purification of the recombinant GAD proteins
by affinity chromatography with a metal-chelating matrix
(22). The autoantigenicity of both recombinant human
GAD66 and GAD67 was examined by immunoprecipitation
using sera of patients with recent-onset IDDM.
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MATERIALS AND METHODS
Isolation and Characterization of GADt6 and GAD67
cDNA Clones—cDNA clones coding for the human GAD65
and GADe7 were isolated from a human pancreas cDNA
library in A-gtll (Clontech) or a human hippocampus
cDNA library in A-ZAPII (Stratagene) by PCR amplifi-
cation. Both the 5'-PCR primer (5'-TCTCTCCCGGGATC-
CGAGCTGATGGCITCTTCIACICCTTC-3') and the 3'-
PCR primer (5'-TCTCTCGGTACCTCGAGTTACAGATC-
CTGGICCAGTCTTTCTATC/TTCCTC-3') were designed
to add terminal restriction sites for cloning purposes and
corresponded to the homologous cDNA sequence of the
published rat brain 67 kDa GAD (23). For PCR amplifi-
cation recombinant DNA was isolated from 2 X 10s plaques
of the A -cDNA libraries according to a standard protocol
with a A-phage DNA isolation kit (Quiagen). A total of 1.0
ptg of recombinant cDNA was amplified with 2 units of Taq
polymerase (Amersham) in a 100/^1 reaction mixture
comprising 10 mM Tris/HCl, pH 8.0, 50 mM KC1, 1.5 mM
MgCl2, 4pmol of each primer, and 100/xM dNTPs. The
amplification reaction was carried out for 30 cycles with the
following cycling times: denaturation, 1 min at 95°C,
annealing, 2 min at 60°C, and primer extension, 2 min at
72°C. Additional 3'-PCR primers were designed to add the
coding sequence (CATCACCATCACCATCAC) for the
histidine-hexapeptides at the 3'-ends of both isolated GAD
cDNAs.
Expression of Human GAD65 and GAD67 in Sf9 Cells—
The isolated cDNAs coding for either full-length human
GAD66 or GAD67 were inserted into baculovirus transfer
vector pVL1393 (Invitrogen) to construct cDNA clones
coding for recombinant fusion proteins with GAD66 and
GAD67 at their N-termini and histidine-hexapeptides at
their C-termini, respectively. Spodoptera frugiperda (Sf9)
cells were cotransfected with the recombinant transfer
vectors and the linearized wild type baculovirus Autogra-
pha califomica by lipofection at a density of 1.6 X 106 cells/
ml with a multiplicity of infection (MOI) of 5 according to
general baculovirus methods (24-26). After plaque puri-
fication, positive recombinant baculovirus clones were
selected for expression according to standard protocols
(27). The infected Sf9 cells were grown in SF900 medium
(Gibco) containing 0.04% fetal calf serum as a suspension
culture for 48 h prior to harvesting. Extracts of Sf9 cells
infected only with the wild type virus and non-recombinant
pLV1393 were used as controls (MOCK).
Purification of Recombinant Human GADtb and
GADt7—Infected Sf9 cells were cultured as a suspension in
SF900 medium (Gibco) containing 0.04% fetal calf serum
for 48 h and then sedimented prior to lysis. About 8 ml of
sedimented cells was resuspended in 30 ml of lysis buffer
(20 mM Tris/HCl, pH 7.4, 1 mM PMSF, 1 mM AET, 0.02
mM PLP, and 2 /*g/ml of the proteinase inhibitors, leupep-
tin, aprotinin, bestatin, and pepstatin), homogenized with
10 strokes of a glass-teflon homogenizer at 0*C, and then
separated into soluble and insoluble cell fractions by
centrifugation at 100,000 Xg and 4'C for 30 min. The
supernatant was adjusted to 40 mM Tris/HCl, pH 7.6, and
0.5 M NaCl, and then directly applied onto a chelating
Sepharose-FF column charged with nickel ions according to
the manufacturer's standard protocol (Pharmacia). The
loaded column was developed with 10, 30, and 500 mM
imidazole in lysis buffer containing 0.5 M NaCl. The
recombinant GAD proteins eluted with 500 mM imidazole
were supplemented with 40% sucrose and directly used for
immunological assays.
Western Blotting Analysis of Recombinant GADSS and
GAD67— The protein fractions were separated by 10%
SDS-PAGE under reducing conditions and then transferred
to nitrocellulose filters (Amersham) using a trans-blot
semi-dry electrophoretic transfer cell (Bio-Rad). The
unoccupied protein-binding sites on the filters were blocked
with 5% nonfat drid milk in TBST-buffer (10 mM Tris/
HC1, pH8.0, 150 mM NaCl, 0.05% Tween-20). The im-
mobilized proteins were incubated for 90 min with 500-fold
dilutions of autoimmune sera. The bound antibodies were
visualized with anti-human immunoglobulins conjugated
with alkaline phosphatase (Promega) as previously de-
scribed (22).
Immunoprecipitation of Metabolically Labeled GAD6S
and GAD67—Approximately 5x 10" infected Sf9 cells per
culture dish of 100 mm diameter were cultured in Grace's
medium (Gibco) containing 10% fetal calf serum for 36 h at
27°C prior to adjustment of the cells to a medium free of
serum and methionine for 60 min and subsequent labeling
with 10 ml serum-free medium containing 200 //Ci [36S]-
methionine for an additional 6 h at 27*C. The cells were
lysed with 0.5 ml of hypotonic buffer (20 mM potassium
phosphate, pH 7.0, 2 mM EDTA, 2 mM PMSF, 1 mM AET,
2 .wg/ml aprotinin, 0.2 mM PLP) and then centrifuged at
100,000 X g for 30 min. The pellets were resuspended in 20
mM potassium phosphate, pH 7.2, 150 mM NaCl, 2 mM
EDTA, 2 mM PMSF, 1% Trasylol, 1% Triton X-100 for 2 h
at 4*C followed by centrifugation at 33,000 X g for 30 min.
One hundred microliter aliquots of the supernatants were
mixed with 25 //I of antiserum and then incubated over-
night at 4*C. The immune complexes were bound to 30 mg
of protein A-Sepharose (Pharmacia) at 4'C for 2 h, washed
sequentially with wash-buffer (100 mM Tris/HCl, pH 9.0,
500 mM LiCl, 1% 2-mercaptoethanol, 1% Triton X-100)
and PBS, and then eluted and separated by 10% SDS-
PAGE, followed by fluorography (10). All sera tested for
immunoprecipitation had been pre-cleared with a pool of
normal human sera prior to precipitation with the H)DM
patient sera (10).
Measurement of the Enzyme Activities of Recombinant
GAD6S and GADS7—GAD activity was measured according
to the protocol of Krieger and Heller (28). The production
of [14C]CO2 on decarboxylation of 0.1 /<Ci L-[l-uC]glu-
tamate (Amersham) was determined in 200 //I of tissue or
cell homogenates in cell-lysis buffer (50 mM KH2PO4, pH
7.0, 1 mM EDTA, 1 mM AET, 0.2 mM PLP, 1% Triton
X-100). The GAD activity was calibrated with respect to
both incubation time and protein concentration, and ex-
pressed as mU/mg total cellular protein (1 unit= 1 ft mol
[14C]CO2/min).
Anti-GAD Antibodies—All autoimmune sera tested in
the present study were derived from recently diagnosed
EDDM patients, and were assayed for anti-GADs6 auto-
antibodies by immunoprecipitation using isolated porcine
pancreatic islet cells after metabolical labeling with [3BS]-
methionine (5, 10). The patient serum designated as
anti-GAD924 was found to be strongly reactive with linear
autoantigenic epitope(s) of the human GAD,S (29), and
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therefore selected for Western blotting analysis of the
expressed recombinant GAD66. A mouse monoclonal anti-
GAD antibody specific for GAD67 was generated against a
bacterially expressed and purified GAD67 peptide of 46
amino acids in length, and generously made available by
Drs. B. Ziegler and M. Ziegler (Institute of Diabetes,
University of Greifswald, Karlsburg, Germany). The
culture supernatant of a corresponding mouse hybridoma
cell line containing the monoclonal anti-GAD67 antibody
was diluted 200-fold for Western blotting analysis.
RESULTS
Isolation and Characterization of Human GADt5 and
GADi7 cDNA Clones—DNAs coding for human GAD65 and
GAD67 were isolated from human pancreas and hippocam-
pus cDNA libraries by PCR amplification based on the
homologous sequence of published rat brain GAD65 cDNA,
respectively (23). cDNA fragments of 1.788 and 1.819 kb
in length coding for 585 and 594 amino acids of GAD65 and
GAD67 were confirmed by DNA sequence analysis, respec-
tively (Fig. 1). At the nucleotide level, the human GAD66
and GAD67 cDNAs revealed sequence homology of 64.1%,
and were 62.9 and 90.1% identical to the rat brain GAD67
cDNA, respectively (23). At the amino acid level, the
human GAD66 and GAD67 exhibited an overall sequence
homology of 64%.
Expression of Human GADK and GAD67 in Sf9 Insect
Cells and Their Western Blotting Analysis—Both the 1.788
kb GAD66 cDNA and 1.819 kb GAD67 cDNA were inserted
into baculovirus transfer vector pVL1393 for the infection
of Sf9 insect cells. The obtained constructs, pAcGAD2 and
1819 bp
1788 bp
1 2
Fig. 1. PCR amplification of cDNAs coding for human GAD86
and GAD,7. The total input of 1.0//g of recombinant DNA derived
from human hippocampus (lane 1) and human pancreas cDNA
libraries (lane 2) was amplified by PCR. Aliquots of 10 //I from the
PCR reaction mixture (100 //I) were separated in an 1% agarose gel
and visualized by staining with ethidium bromide. A 1,819 bp band
(lane 1) and a 1,788 bp band (lane 2) representing full-length cDNAs
coding for human GAD87 and GADM were obtained, respectively. Size
markers (M).
B
29.0 —
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Fig. 2. Expression and Western blotting analysis of human
GADM and GAD,, derived from Sf9 insect cells. Infected Sf9 cells
were cultured for 48 h, and then lysed in buffer containing 0.3%
Nonidet P-40 by freezing and thawing. The homogenate was separated
into soluble and insoluble cell fractions by centrifugation. Aliquots
representing approximately 105 cells were separated by 10% SDS-
PAGE and stained Coomassie Brilliant Blue (A) or analyzed by
Western blotting using the anti-GAD924 serum from a patient with
IDDM (B) or the mouse monoclonal anti-GAD,7 antibody (C). Size
markera (M). Soluble (lane 1) and insoluble fraction of MOCK cells
(lane 2), soluble (lane 3) and insoluble fraction of GADM-expressing
Sf9 cells (lane 4), soluble (lane 5) and insoluble fraction of GAD,7-
expressing Sf9 cells (lane 6), and 2.5 u g of purified G ADM (lane 7) and
GAD»7 (lane 8), respectively.
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Fig. 3. Measurement of GAD activities in infected Sf9 insect
cells. Sf9 cells infected with the wild type baculovirus (MOCK), Sf9
cells expressing GAD,5 (GAD06-Sf9) and GAD,7 (GAD,7-Sf9), isolated
porcine pancreatic islet cells and porcine brain were homogenized and
used for the measurement of GAD activities.
1 . • • • :
9 10 11 12
kDa
- 116.0
- 97.0
• 68.0
• 43.0
31.0
• 21.0
pAcGADl, directed the high-level expression of recom-
binant fusion proteins of human GAD6B and GAD87 with
histidine-hexapeptides at their C-termini and with the
expected apparent molecular masses under the control of
the baculovirus polyhedrin promoter, respectively (24).
Western blotting analysis with either a GAD66-specific
autoimmune serum from a patient with EDDM designated
as anti-GAD924 (Fig. 2B) or with a GAD67-specific mouse
monoclonal anti-GAD antibody (Fig. 2C) demonstrated
that infected Sf9 cells synthesized the recombinant GAD85
and GAD67 as both soluble and insoluble proteins (Fig. 2,
lanes 3 and 4, and 5 and 6). No expression of any GAD
isoform was detected in the control Sf9 cells (MOCK)
infected only with the non-recombinant vector (Fig. 2,
lanes 1 and 2). The smaller bands probably represent
premature translation-termination events and/or limited
degradation of the recombinant GAD proteins.
Enzyme Activities of Expressed Human GAD65 and
GAD67—The recombinant human GAD66 and GAD67 ex-
pressed by the baculovirus in Sf9 cells were examined for
enzyme activity in order to determine their biological
nature and conformation in comparison with natural GAD
isolated from porcine islet cells and porcine brain. As shown
in Fig. 3, both the infected Sf9 cell lines producing human
GAD.B (GAD65-Sf9) andGAD67 (GAD67-Sf9), respective-
ly, exhibited approximately 370 and 45-fold, and 600 and
75-fold increases in GAD enzyme activity as measured in
porcine islet cells and brain, respectively. No GAD activity
was detectable in control Sf9 cells (MOCK).
Purification of Recombinant Human GADti and
GAD67— The recombinant human GAD66 and GAD67 mole-
cules were expressed as histidine-hexapeptide fusion
proteins to ensure a simplified purification protocol. The
method involves single-step affinity chromatography of the
soluble cell fraction using a metal-chelating matrix charged
with Ni2+ ions {22). To maintain natural-like conformation
of both GAD forms, the chromatography of the recom-
binant proteins was modified, being carried out at physio-
Fig. 4. Immnnoprecipitation of recombinant human GAD85
and GAD,7 with IDDM patient sera. Soluble cell fractions of
metabolically labeled recombinant Sf9 cell cultures expressing
human GAD,6 (A) and GAD»7 (B) were analyzed by immunoprecipita-
tion using sera from patients with recently diagnosed IDDM (lanes 1-
10) or with two sera from healthy individuals (lanes 11 and 12).
Lysates of corresponding infected Sf9 cells were analyzed prior to
immunoprecipitation (lane 13). The proteins were separated by 10%
SDS-PAGE and visualized by fluorography.
logical pH and without any detergents. The bound recom-
binant GAD66 and GAD67 proteins were eluted from the
matrix with 0.5 M imidazole (30). The method allowed
highly feasible and efficient isolation of recombinant GAD66
and GAD67 proteins with purities approaching homogene-
ity, as shown by SDS-PAGE and Western blotting analysis
(Fig. 2, lanes 7 and 8). About 3-5 mg of each soluble
recombinant protein, GAD66 and GAD67 was isolated from
1,000 ml of suspension culture of infected Sf9 cells.
Immunoprecipitation of Recombinant Human GAD65 and
GAD67 with IDDM Patient Sera—Sera from patients with
newly diagnosed IDDM who previously showed high titers
of anti-GAD8S autoantibodies on immunoprecipitation of
metabolically labeled porcine islet cells (10) were used to
demonstrate the corresponding antigenicity of the recom-
binant human GAD65 as well as GAD67. Infected Sf9 cells
were radioactively labeled with [35S]methionine and then
immunoprecipitated with either ten sera from patients
with IDDM or two sera from healthy individuals (Fig. 4).
All of the selected IDDM sera precipitated the recombinant
GAD66 (Fig. 4A, lanes 1-10). Only two (20%) of the same
ten IDDM sera actually recognized additionally the recom-
binant GAD67 (Fig. 4B, lanes 4 and 5). No immuno-
precipitation of either recombinant GAD protein was
observed with control sera (Fig. 4, lanes 11 and 12).
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DISCUSSION
Unlike other autoimmune endocrinopathies, insulin-depen-
dent diabetes mellitus (IDDM) usually strikes the very
young with many severe complications, including major
morbidity and mortality (6, 10, 31). The future goal of
diabetes type 1 research is to elucidate the molecular
mechanisms involved in the early establishment and
pathogenesis of IDDM. From the clinical perspective, two
main goals are important. One is to obtain more detailed
knowledge for the early diagnosis of the disease, and the
other is to increase the knowledge on the pathology and
origin of the disease, and the possibilities to improve
therapeutic methods, respectively.
The diagnostic implications are of major importance for
a disease such as EDDM, which appears to be a very slow
process and remains asymptomatic for a long preclinical
period. Several groups have reported that islet cell specific
antibodies are significant markers, and have identified
individuals with a high risk for IDDM (5-11). One of the
earliest detectable islet cell autoantibodies is the anti-
GAD65 autoantibody, which could be highly predictive for
the development of IDDM (6). In pancreatic y9-cells two
GAD proteins were identified, with apparent molecular
weights of 65 kDa (GAD6B) and 67 kDa (GAD67), which are
both autoantigenic (17, 18, 20, 32). Current immunoassays
such as immunofluorescence and immunoprecipitation ones
involve frozen sections of pancreas or a suspension of
isolated pancreatic islet cells as antigenic substrates for the
detection of autoantibodies to GAD, respectively. These
assay systems depend on the wide variability of the antigen
concentration in human or animal tissues, leading to incon-
sistent test results. Because of the limited amounts and
purity of the two GAD forms, the discrimination on
measurement of the autoantibodies to GAD66 and GAD67 is
hardly possible. It is thus be of importance to develop an
alternative and specific immunoassay system (ELISA)
which involves either purified recombinant human GAD66
or GAD57 as an antigenic target in order to eliminate all
disadvantages caused by natural GAD sources.
The repertoire of expression systems available for the
production of foreign recombinant proteins is large, and
extends to several examples of bacterial, yeast, and
mammalian cell systems. The choice of the best expression
system for a particular gene product is therefore some-
times difficult, and should be based on certain criteria such
as the yield and biological activity of the recombinant
proteins. Several approaches involving bacterial expres-
sion systems for the synthesis of recombinant human
GAD6s and GAD87 as antigenic targets for immunoassays
were only partly,successful (18). The main bulk of recom-
binant GAD expressed in bacteria lacked the correct
modifications and conformation, and was thus not recog-
nized representatively by sera from patients with IDDM,
indicating the importance of conformational antigenic
epitopes within the GAD proteins (13). Less than 20% of
the IDDM patients developed autoantibodies which were
able to react with the recombinant GAD66 derived from
Escherichia coli (29).
Alternatively, the baculovirus expression system has
turned out to be a very powerful system for the production
of large quantities of biologically active proteins that
eliminates all problems caused by prokaryotic expression
systems. The baculovirus-mediated expression in Sf9
insect cells has been demonstrated to be capable of correct
posttranslational modifications (33). Furthermore, the
system is easy to scale up as a suspension culture under
serum-free conditions. In the present paper we described
the isolation of full-length cDNAs coding for human GAD66
and GADS7, and their expression as recombinant GAD
fusion proteins with histidine-hexapeptide moieties at
their C-termini. Based on the specific complex formation
between the histidine-hexapeptide moiety and the Ni2+
ions of a metal-chelating matrix the recombinant proteins
were specifically purified to near homogeneity from the
cytosolic cell fraction by single-step affinity chromatog-
raphy (22).
The availability of the recombinant human GAD66 and
GAD67 for immunoassays for a significantly early diagnosis
of IDDM appears to rely on a natural-like conformation
which may correspond to their autoantigenicities. There-
fore, it was necessary to demonstrate the ability of the
baculovirus expression system to produce the human
GAD6B and GAD67 as biologically active proteins regarding
their enzymatic activities and their immunoreactivities
with sera from patients with clinically defined IDDM. Both
the recombinant GAD66 and GAD67 fusion proteins exhibit-
ed enzyme activities in lysates of infected Sf9 cells that
were about 400 to 600 times and 45 to 75 times as great as
those of extracts of porcine islet cells and porcine brain,
which are normally used as natural GAD sources for
current immunoassays (Fig. 3). The immunoprecipitation
of recombinant GAD85 and GAD67 produced in Sf9 cells
correlated very well with previously described results (20).
All ten conventionally characterized sera from patients
with recent-onset IDDM (5, 20) were also able to specifi-
cally immunoprecipitate the recombinant GAD85 fusion
protein derived from infected Sf9 cells (Fig. 4A), whereas
only 20% could additionally recognize the recombinant
GADS7 (Fig. 4B). Therefore, GAD67 seems to be of minor
importance as an autoantigenic tool for the diagnosis of
IDDM (20).
As shown in the present paper recombinant human GAD
proteins derived from baculovirus-infected Sf9 cells meet
all requirements of a suitable source of antigens which may
replace conventially purified GAD from human and animal
tissues in order to assay anti-GAD autoantibodies for the
diagnosis of prediabetic insulitis and IDDM. In conclusion,
the present results demonstrated that the recombinant
human GAD65 and GAD67 were produced in a natural-like
conformation with fully restored enzyme activities and
autoantigenicities (20). So far, no influence on the autoanti-
genicity and enzyme activity of recombinant GAD proteins
was observed due to the fusion with the histidine-
hexapeptide. The designed histidine-hexapeptide fusion
proteins provide for the first time the possibility of the
simple and efficient purification of recombinant human
GAD6S and GAD67. The availability of simple immunoas-
says such as ELISA with purified recombinant GAD85 will
be of importance for the screening of large populations in
order to learn more about the etiology of IDDM as well as
for an early diagnosis, which will allow therapeutic inter-
vention before most of the pancreatic y9-cells are destroyed.
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